lexiara

22.

Issues regarding labelling and the unblinding of investigational medicinal products shall be addressed in the protocol, where necessary.

· All articles ·

Source: EUR-Lex (Cellar) · retrieved 2026-11-06 · Text as adopted (Official Journal); later amendments are not incorporated in this text.